Therapy of B-cell malignancies by anti–HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways

A humanized IgG4 anti–HLA-DR monoclonal antibody (IMMU-114), engineered to avoid side effects associated with complement activation, was examined for binding and cytotoxicity on leukemia, lymphoma, and multiple myeloma cell lines and chronic lymphocytic leukemia (CLL) patient specimens, followed by...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Stein, Rhona, Gupta, Pankaj, Chen, Xiaochuan, Cardillo, Thomas M., Furman, Richard R., Chen, Susan, Chang, Chien-Hsing, Goldenberg, David M.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2010
Materias:
Lymphoid Neoplasia
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2892948/
https://ncbi.nlm.nih.gov/pubmed/20101022
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-06-228288
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares